Danish biotech company Egalet appoints new chairman and new CEO

05-Sep-2007

The Board of Directors of the Danish specialty pharmaceutical company Egalet and the company's principal shareholders have asked Michael Fiorini to step in as the company's new chairman. Michael Fiorini, replaces Egalet's existing chairman, Seppo Mäkinen of Bio Fund Management ltd, who has chaired the board since 2005. Egalet has also appointed Peter Nordkild, formerly Chief Commercial Officer of Pharmexa, as Chief Executive Officer.

Michael Fiorini (59) is the former CEO of The East Asiatic Company and a senior executive with A.P. Møller Mærsk.

Seppo Mäkinen remains a member of Egalet's board of directors with Regina Hodits, Atlas Venture, Francesco De Rubertis, Index Ventures and Jan-Eric Österlund, QueQuoin Holdings.

In addition, Egalet has employed Peter Nordkild (52) as its new Chief Executive Officer. Peter Nordkild was previously Chief Commercial Officer of the listed Danish biotech company Pharmexa. Before joining Pharmexa, he held a position as Senior Vice President with Ferring Pharmaceuticals..

Peter Nordkild will supersede Jan Quistgaard, a co-founder and co-owner of Egalet, during September. Jan Quistgaard will continue as external advisor to the management of Egalet.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials - New Patent Broadens Company’s Existing Protection of Optimized RNAi Molecules Including Proprietary AtuRNAi Platform

Biofrontera received official review of its drug approval dossier for BF-200 ALA

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

Evotec and Novo Nordisk form research alliance in diabetes and obesity

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema - Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor